US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Militia Long/Short Equity ETF

29.50

+0.39001.34%

Volume:23.63K

Turnover:696.09K

Market Cap:- -

PE:- -

High:29.71

Open:29.71

Low:29.30

Close:29.11

Loading ...

Overview Company News Filings

Elevation Oncology to Discontinue Development of EO-3021; Advancing EO-1022, While Evaluating Strategic Options

Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Press Release: Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer

Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors

Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer

ELAHERE® (mirvetuximab soravtansine-gynx) Shows Consistent Survival Benefit in Long-Term Analysis for Certain Ovarian Cancer Patients

Press Release: Cellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate Update

Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update

Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38

Press Release: Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results

Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024

Press Release: Oncolytics Biotech(R) Reports Highlights and Financial Results for Q4 and Year-End 2024

Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma

HUTCHMED Announces that it has Completed Enrollment of a Phase II Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in China

IO Biotech Reports 2024 Business Highlights

Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications

Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) previously treated with a BTK inhibitor

ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ORR/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ORR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","market":"US","secType":"STK","nameCN":"Militia Long/Short Equity ETF","latestPrice":29.5,"timestamp":1751054400000,"preClose":29.11,"halted":0,"volume":23629,"delay":0,"floatShares":2870000,"shares":0,"eps":0,"marketStatus":"Pre-Mkt","change":0.39,"latestTime":"06-30 06:16:07 EDT","open":29.71,"high":29.71,"low":29.3,"amount":696091.5463,"amplitude":0.014085,"askPrice":47.2,"askSize":200,"bidPrice":28.8,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1751290200000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":29.5,"sharesOutstanding":2870000,"nav":29.02,"aum":83287400,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":29.5,"preClose":29.5,"latestTime":"16:00 EDT","volume":15,"amount":442.5,"timestamp":1751054402295},"volumeRatio":1.0280451084091622},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","floatShares":2870000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.0280451084091622,"shares":0,"dividePrice":0,"high":29.71,"amplitude":0.014085,"preClose":29.11,"low":29.3,"week52Low":25.63,"pbRate":"--","week52High":29.71,"institutionHeld":0,"latestPrice":29.5,"committee":-0.333333,"eps":0,"divideRate":0,"volume":23629,"delay":0,"ttmEps":0,"open":29.71,"prevYearClose":25.88,"prevWeekClose":29.5,"prevMonthClose":28.1031,"prevQuarterClose":27.84,"fiveDayClose":28.65,"twentyDayClose":28.2522,"sixtyDayClose":27.92},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORR\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2520557704","title":"Elevation Oncology to Discontinue Development of EO-3021; Advancing EO-1022, While Evaluating Strategic Options","url":"https://stock-news.laohu8.com/highlight/detail?id=2520557704","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520557704?lang=en_us&edition=fundamental","pubTime":"2025-03-20 20:00","pubTimestamp":1742472000,"startTime":"0","endTime":"0","summary":"-- Continuing to advance potentially differentiated HER3 ADC, EO-1022, which utilizes an MMAE payload and glycan site-specific conjugation ---- Plan to present preclinical data for EO-1022 at AACR Annual Meeting 2025 and to file an Investigational New Drug  application in 2026 ---- Updated clinical data of Claudin 18.2 ADC EO-3021 demonstrate ORR of 22.2% in biomarker-enriched patient population; electing to discontinue further development of EO-3021 ---- Implementing workforce reduction of approximately 70%; cash runway extended into 2H 2026 --. Mr. Ferra continued, \"We are turning our focus to our potentially differentiated HER3 ADC, EO-1022, which incorporates glycan site-specific conjugation and is desig","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/elevation-oncology-discontinue-development-eo-120000342.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/elevation-oncology-discontinue-development-eo-120000342.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ORR","BK4080","BK4231","ADC","BK4539","BK4139","ELEV"],"gpt_icon":0},{"id":"2520693218","title":"Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2520693218","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520693218?lang=en_us&edition=fundamental","pubTime":"2025-03-19 04:29","pubTimestamp":1742329740,"startTime":"0","endTime":"0","summary":"Significant progress in preclinical pipeline targeting KRAS-driven solid tumor cancers with systemic administration demonstrating robust anti-tumor and anti-metastasis activity in orthotopic mouse mod","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/18/3044999/0/en/Silexion-Therapeutics-Reports-Full-Year-2024-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","LENZ","SLXN","BK4139"],"gpt_icon":0},{"id":"2520621313","title":"Press Release: Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2520621313","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520621313?lang=en_us&edition=fundamental","pubTime":"2025-03-18 19:30","pubTimestamp":1742297400,"startTime":"0","endTime":"0","summary":"- Recently reported positive preliminary data from Phase 1 dose escalation trial of micvotabart pelidotin , including a confirmed 50% objective response rate by RECIST 1.1 in recurrent and metastatic head and neck squamous cell carcinoma . - Received Fast Track Designation from the U.S. Food and Drug Administration for MICVO for the treatment of adult patients with R/M HNSCC whose disease has progressed following treatment with platinum-based chemotherapy and an anti-PD-1 therapy. - Initiated monotherapy expansion cohorts of MICVO for 2L and 3L R/M HNSCC patients who have received prior platinum-based chemotherapy and prior PD-1 inhibitor therapy with preliminary data expected in 2H25 and 2/3L R/M HNSCC patients who have received prior EGFRi and PD-1 inhibitor therapy with preliminary data expected 1H26","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0238689110.USD","LU1934455863.HKD","LU1585245621.USD","LU1057294990.SGD","LU2468319806.SGD","LU1066051811.HKD","LU0053666078.USD","R","LU1093756325.SGD","LU0006306889.USD","BK4550","LU2106854487.HKD","IE000M9KFDE8.USD","SG9999015358.SGD","LU1941712264.USD","SG9999015341.SGD","LU1917777945.USD","LU2324357040.USD","MRK","SG9999001176.USD","LU2461242641.AUD","L","IE0009355771.USD","LU1699723380.USD","LU2361044949.HKD","IE00B4R5TH58.HKD","LU1983299246.USD","LU2089984988.USD","ORR","LU2361044865.SGD","IE00BJT1NW94.SGD","ADC","LU0203345920.USD","LU2112291526.USD","LU0070302665.USD","LU0320765646.SGD","LU1934455194.USD","BK4080","PYXS","IE00B2B36J28.USD","IE00BBT3K403.USD","BK4007","SG9999002232.USD","BK4516","LU1430594728.SGD","LU2023250843.SGD","IE00BFTCPJ56.SGD","LU1066051225.USD","SG9999002224.SGD","IE00BJJMRZ35.SGD"],"gpt_icon":0},{"id":"2520757296","title":"Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2520757296","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520757296?lang=en_us&edition=fundamental","pubTime":"2025-03-18 00:19","pubTimestamp":1742228340,"startTime":"0","endTime":"0","summary":"Results from Phase 2 RAINFOLTM-01 trial  showed that with a median on-study follow-up of 48 weeks, Rina-S 120 mg/m2 led to a confirmed objective response rate  of 55.6% and median duration of response  was not reached. The B1 cohort is a dose expansion study in patients with histologically or cytologically confirmed advanced OC . Rina-S 120 mg/m2 Q3W at a median on-study follow-up of 48 weeks showed encouraging antitumor activity; the confirmed ORR was 55.6% , the disease control rate  was 88.9% , and the median duration of response  was not reached . In the 18 patients evaluable for response treated with 120 mg/m2 Q3W, complete responses were observed in 4 patients  and 8 patients experienced confirmed partial responses . Most responses with Rina-S 120 mg/m2 were observed early . Only one patient in the 120 mg/m2 treatment arm was not evaluable. In the Rina-S 100 mg/m2 Q3W treatment arm , at a median on study follow-up of 46 weeks, the confirmed ORR was 22.7% , the DCR was 86.4% , and","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/investigational-rinatabart-sesutecan-rina-continues-161900141.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B7SZL793.SGD","PLD","BK4585","LU0868494617.USD","LU1974910355.USD","BK4231","IE0031619046.USD","LU2298321311.HKD","LU2360108059.USD","LU1917777945.USD","LU2048586759.USD","IE00B2PGVK34.USD","BK4139","GMAB","BK4007","BK4157","BK4080","LU2106854487.HKD","BK4567","IE00B19Z4B17.USD","LU2092937221.SGD","BK4224","ADC","AEIS","IE00B66KJ199.SGD","LU2023250504.SGD","BK4588","PROC","LU2023250843.SGD","BK4534","BK4171","BK4086","LU2041044095.USD","ORR","OC","IE00B3CCJ633.GBP","IE00BGHQF417.EUR"],"gpt_icon":0},{"id":"2520406275","title":"Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2520406275","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520406275?lang=en_us&edition=fundamental","pubTime":"2025-03-17 20:00","pubTimestamp":1742212800,"startTime":"0","endTime":"0","summary":"Antitumor activity observed with confirmed partial responses in 50% of patientsat highest dose tested to date, across multiple tumor types PLN-101095 was generally well tolerated across all doses SOUT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/17/3043649/0/en/Pliant-Therapeutics-Announces-Interim-Phase-1-Data-for-PLN-101095-in-Patients-with-Immune-Checkpoint-Inhibitor-Refractory-Advanced-Solid-Tumors.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0359202008.SGD","BK4531","BK4565","IE00B19Z4B17.USD","IE00B7SZL793.SGD","LU0359201612.USD","IE00BYTNYN87.SGD","BK4548","01698","BK4535","BK4108","IE00B66KJ199.SGD","BK4563","TME","CD","IE00BYQNZ168.SGD","ORR","LU1023057109.AUD","BK4526","SG9999011746.SGD","AEIS","LENZ","BK4139","BK4157","IE00B12V2V27.USD","BK4571","BK4509","BK4552","BK4116","LU2039709279.SGD","IE0031619046.USD"],"gpt_icon":0},{"id":"2519314984","title":"Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2519314984","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519314984?lang=en_us&edition=fundamental","pubTime":"2025-03-15 23:25","pubTimestamp":1742052300,"startTime":"0","endTime":"0","summary":"Azenosertib median duration of response  updated to 6.3 months in the ongoing DENALI Part 1b clinical trial in patients with platinum-resistant ovarian cancer  and continues to demonstrate an objective response rate  of ~35% in response-evaluable patients. On track to initiate Part 2 of the ongoing DENALI clinical trial in 1H 2025, with registration-intent topline data anticipated by year end 2026. As of the January 13, 2025 data cutoff, the safety and tolerability profile was consistent with the safety and tolerability profile from the Company’s January 29, 2025 investor event, which included data based off a cutoff date of December 2, 2024, with no new safety findings. Gastrointestinal toxicities and fatigue were found to be the most common treatment-related adverse events.“The presentation of the updated DENALI Part 1b data at the SGO Annual Meeting supports our continued development of azenosertib,” said Ingmar Bruns, M.D., Chief Medical Officer of Zentalis. “The clear anti-tumor a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zentalis-pharmaceuticals-presents-updated-clinical-152500846.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ZNTL","BK4007","PROC","ORR","BK4139"],"gpt_icon":1},{"id":"2519313450","title":"ELAHERE® (mirvetuximab soravtansine-gynx) Shows Consistent Survival Benefit in Long-Term Analysis for Certain Ovarian Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2519313450","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519313450?lang=en_us&edition=fundamental","pubTime":"2025-03-15 20:00","pubTimestamp":1742040000,"startTime":"0","endTime":"0","summary":"Final data analysis from Phase 3 MIRASOL trial after 30.5-month median follow-up demonstrated 32% reduction in risk of death with ELAHERE compared to chemotherapy in folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer . Data presented in a late-breaking oral presentation at the Society of Gynecologic Oncology  Annual Meeting on Women's Cancer in Seattle. \"Ovarian cancer can be devastating, and when cancer cells stop responding to chemotherapy patients may feel hopeless about their journey. The data presented today reinforce the importance of ELAHERE as a transformative therapy for patients with limited options,\" said Svetlana Kobina, MD, PhD, vice president, oncology medical affairs, AbbVie. \"We remain steadfast in our commitment to bring forward innovative therapies that improve the lives of patients with difficult-to-treat cancers.\". In the United States, ovarian cancer is the leading cause of death from gynecological cancers.3 Each year, approximately 20,000 women","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/elahere-mirvetuximab-soravtansine-gynx-shows-120000918.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/elahere-mirvetuximab-soravtansine-gynx-shows-120000918.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1267930573.SGD","BK4195","LU1244550221.USD","ORR","BK4533","LU0965508806.USD","LU2089984988.USD","LU0795875086.SGD","LU1244550494.USD","LU2237443978.SGD","LU1430594728.SGD","BK4550","PFS","LU1934455277.USD","LU1037948897.HKD","LU0320765646.SGD","LU0417517546.SGD","IE00B4R5TH58.HKD","LU1003077747.HKD","LU1989772840.SGD","SG9999015986.USD","SG9999015952.SGD","BK4581","LU0985320562.USD","LU0820561818.USD","BK4080","BK4585","LU0170899867.USD","IE00BJJMRZ35.SGD","LU0738911758.USD","LU1291159041.SGD","LU1732799900.SGD","LU1162221912.USD","LU1983299246.USD","LU1496350502.SGD","LU1989771016.USD","ADC","LU2237443895.HKD","IE0002141913.USD","LU2089283258.USD","LU0708994859.HKD","LU0545039389.USD","ABBV","LU2112291526.USD","OS","PROC","LU1244550577.SGD","IE00BVYPNV92.GBP","LU1037948541.HKD","LU2237443465.HKD"],"gpt_icon":0},{"id":"2519880824","title":"Press Release: Cellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2519880824","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519880824?lang=en_us&edition=fundamental","pubTime":"2025-03-13 19:05","pubTimestamp":1741863900,"startTime":"0","endTime":"0","summary":"Achieves alignment with U.S. Food and Drug Administration  on regulatory path for potential accelerated approval of iopofosine I 131 as a treatment for Waldenstrm macroglobulinemia . Evaluating timing for Phase 1 solid tumor studies; Auger-emitting radioconjugate prepared for Phase 1b; plans to submit an IND for alpha-emitting radioconjugate;Company to host webcast and conference call at 8:30 AM ET today. FLORHAM PARK, N.J., March 13, 2025  -- Cellectar Biosciences, Inc. , a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the year ended December 31, 2024, and provided a corporate update.-- Finalized confirmatory study design and regulatory pathway for potential. FDA accelerated approval of iopofosine I 131, the Company's targeted. -- The study will be a randomized, controlled trial of iopofosine I. 131 versus a comparator arm, with 100 patients per arm.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNS","LU0289961442.SGD","BK4139","LU2229751404.USD","LU2125910336.SGD","BK4588","LU2240825500.USD","LU2238339852.HKD","BK4120","LU1585245621.USD","LU1989772840.SGD","LU2362541273.HKD","ORR","LU0175139822.USD","LU1721428933.USD","LU0289960550.SGD","BK4585","LU0069063385.USD","03160","WM","CLRB","LU0057025933.USD","LU2125910179.SGD","LU2092937221.SGD","LU0124676726.USD","BK4533","LU2041044095.USD","LU2298064838.USD","TM","LU2023250843.SGD","LU2211814178.USD","LU0347712357.USD","BK4534","LU1917777945.USD","LU2355687059.USD","LU1923621640.USD","LU2413666426.HKD","LU2463526074.USD","LU0689626769.HKD","LU2413666699.HKD","LU1974910355.USD","LU0472753341.HKD","LU1430594728.SGD","LU1989772923.USD","BK4135","BK4566","LU0289739343.SGD","LU2362541513.USD","BK4555","LU0511384066.AUD"],"gpt_icon":0},{"id":"2518788325","title":"Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2518788325","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518788325?lang=en_us&edition=fundamental","pubTime":"2025-03-11 04:12","pubTimestamp":1741637520,"startTime":"0","endTime":"0","summary":"– UDENYCA divestiture on track with Special Meeting of Shareholders taking place March 11, 2025; transaction expected to close late in the first quarter or early in the second quarter of 2025 –。– Post divestiture expected cash of approximately $250 million, with cash runway exceeding two years; Company headcount to be reduced by approximately 30% –。– Catalyst-driven 2025/2026 with multiple clinical data readouts across the Company’s innovative oncology pipeline –。– Conference call today at 5:00 p.m. Eastern Time –。REDWOOD CITY, Calif., March 10, 2025  -- Coherus BioSciences, Inc. , today reported financial results for the fourth quarter and full year 2024 and provided an overview of recent business updates.“Upon the completion of the UDENYCA divestiture and pay-off of our significant debt and royalty obligations, we are projecting a cash position of approximately $250 million,\"continued Mr. Lanfear. “These efforts, combined with organizational streamlining, are expected to provide Cohe","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/coherus-biosciences-reports-fourth-quarter-201200398.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CR","BK4006","HCC","CHSCO","CHRS","BK4139","BK4535","CHSCL","CHSCM","ORR","BK4161","BK4189","CHSCN"],"gpt_icon":0},{"id":"2518220704","title":"Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38","url":"https://stock-news.laohu8.com/highlight/detail?id=2518220704","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518220704?lang=en_us&edition=fundamental","pubTime":"2025-03-10 22:13","pubTimestamp":1741615980,"startTime":"0","endTime":"0","summary":"Company Announcement Johnson & Johnson has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 Genmab will not pursue fu","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/10/3039878/0/en/Genmab-Announces-Johnson-Johnson-Decision-Regarding-HexaBody-CD38.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJJMRZ35.SGD","LU2347655156.SGD","LU1244550494.USD","IE00BGHQF631.EUR","IE00BJT1NW94.SGD","CR","IE00B1BXHZ80.USD","BK4532","IE00B3PB1722.GBP","LU0122379950.USD","LU1778281490.HKD","ORR","LU1066051498.USD","IE0002141913.USD","LU0320765646.SGD","LU1196500208.SGD","LU0795875169.SGD","LU0234570918.USD","LU1674673428.USD","LU1732800096.USD","BK4007","LU2430703251.USD","LU1280957306.USD","LU1059921491.USD","LU1057294990.SGD","IE00BFTCPJ56.SGD","BK4588","IE000M9KFDE8.USD","LU0345770308.USD","LU2129689431.USD","LU1506573853.SGD","IE0002270589.USD","LU1066051811.HKD","JNJ","BK4581","LU2468319806.SGD","LU2505996681.GBP","LU1221951129.SGD","LU1267930813.SGD","BK4592","LU1244550577.SGD","LU0203345920.USD","LU0058720904.USD","LU0640476718.USD","LU0203347892.USD","LU1718418525.SGD","LU1585245621.USD","LU1894683264.USD","LU2089984988.USD","IE00BVYPNV92.GBP"],"gpt_icon":0},{"id":"2518817229","title":"Press Release: Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2518817229","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518817229?lang=en_us&edition=fundamental","pubTime":"2025-03-10 20:57","pubTimestamp":1741611420,"startTime":"0","endTime":"0","summary":"Completed successful clinical trials for CM24 and NT219 oncology assets, demonstrating clinical benefits and identifying potential biomarkers. CM24 is well positioned for personalized treatment, with planned biomarker-driven Phase 2b study based on serum biomarkers CEACAM1 and myeloperoxidase. NT219 headed into Phase 2 head and neck cancer study in combination with pembrolizumab  and in combination with cetuximab . \"We believe that our CAPTN-3 platform is well-positioned and differentiated in the T cell engagers  and multi-specific space, uniquely unleashes both innate and adaptive immune cells against the tumor, demonstrating synergistic effect of the T cell and NK cell activating arms. The unique NKG2A arm in the lead compound acts as a checkpoint inhibitor, enabling simultaneous NK and T cell activation, including effector subsets with high antitumor activity. We are excited about our CAPTN-3 collaboration with the Icahn School of Medicine at Mount Sinai. Our cash runway is expected","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","BK4211","ORR","BK4097","PPBT","PFS","OS","BK4007"],"gpt_icon":0},{"id":"2517919484","title":"Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2517919484","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517919484?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:00","pubTimestamp":1741348800,"startTime":"0","endTime":"0","summary":"BRACELET-1 results in HR+/HER2- metastatic breast cancer surpass expectations, providing meaningful data for a registration-enabling study. Promising Data in Anal Cancer with 33% Response Rate, Including a Durable 15+ Month Complete Response: In the ongoing GOBLET study, Oncolytics' pelareorep combination therapy achieved a 33% objective response rate , including a complete response lasting over 15 months, in twelve evaluable patients with second-line or later unresectable squamous cell carcinoma of the anal canal treated with pelareorep and atezolizumab . This encouraging signal in a very tough-to-treat disease further supports pelareorep's potential in solid tumors. The success criteria in Stage 1 of this Simon two-stage design were previously met; enrollment into Stage 2 of this cohort has begun and will add 18 additional","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/oncolytics-biotech-reports-highlights-financial-120000587.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/oncolytics-biotech-reports-highlights-financial-120000587.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4195","BK4097","PFS","BK4211","ORR","ONCY","OS"],"gpt_icon":0},{"id":"2517481546","title":"Press Release: Oncolytics Biotech(R) Reports Highlights and Financial Results for Q4 and Year-End 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2517481546","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517481546?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:00","pubTimestamp":1741348800,"startTime":"0","endTime":"0","summary":"BRACELET-1 results in HR+/HER2- metastatic breast cancer surpass expectations, providing meaningful data for a registration-enabling study. Data from GOBLET in pancreatic and anal carcinoma support continued development of pelareorep in these indications, with combination studies ongoing. SAN DIEGO and CALGARY, AB, March 7, 2025 /PRNewswire/ -- Oncolytics Biotech  Inc.  , a leading clinical-stage company specializing in immunotherapy for oncology, today reported on highlights and financial results for Q4 and year-end 2024. With its lead candidate, pelareorep, demonstrating strong efficacy signals in breast, pancreatic, and anal cancer, the company is strategically advancing toward registrational studies that could redefine treatment landscapes in multiple high-need indications. All dollar amounts are expressed in Canadian currency unless otherwise noted.GOBLET gastrointestinal cancer data continue to demonstrate pelareorep's potential across multiple indications. Oncolytics presented t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFS","R","BK4022","BK4211","BK4195","BK4097","OS","BK4232","ORR","BK4139","ONCY"],"gpt_icon":0},{"id":"2517438854","title":"Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2517438854","media":"Business Wire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517438854?lang=en_us&edition=fundamental","pubTime":"2025-03-07 19:59","pubTimestamp":1741348740,"startTime":"0","endTime":"0","summary":"Approval based on results of Phase 3 CheckMate -9DW clinical trial demonstrating a statistically significant and clinically meaningful improvement in overall survival with Opdivo plus Yervoy compared to investigator’s choice of lenvatinib or sorafenib. PRINCETON, N.J., March 07, 2025----Bristol Myers Squibb  today announced that the European Commission  has approved Opdivo  plus Yervoy  for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma .\"The European Commission’s approval for Opdivo plus Yervoy adds to the growing body of evidence demonstrating the value of dual immunotherapy and represents an important new treatment option that may extend survival for patients with hepatocellular carcinoma,\" said Dana Walker, M.D., M.S.C.E., vice president, Opdivo global program lead, Bristol Myers Squibb. \"This approval marks a critical milestone in our commitment to improving outcomes for patients with liver cancer. We look forward to bringing this","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bristol-myers-squibb-receives-european-115900243.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B7SZL793.SGD","LU0096364046.USD","LU0114720955.EUR","LU1291159041.SGD","LU0868494617.USD","ALK","BK4201","LU1670711040.USD","LU0306807586.USD","BK4581","CRT","LU0306806265.USD","BK4532","BMY","HCC","EC","TEN","LU1571399168.USD","BK4097","LU0321505868.SGD","HSCT","LU2125154935.USD","LU1430594728.SGD","LU0237698245.USD","OS","VOD","MYE","BK4124","BK4213","LU1670710588.SGD","LU0061475181.USD","IE00B19Z4B17.USD","CRC","LU1868837300.USD","LU1868837136.USD","LU1868836914.USD","BK4132","RCC","LU1261432733.SGD","IE00BSNM7G36.USD","LU1868836591.USD","LU2242646821.SGD","LU0321505439.SGD","BK4157","ORR","LU1032466523.USD","LU0225284248.USD","IE00BFTCPJ56.SGD","AEIS"],"gpt_icon":0},{"id":"2517132956","title":"HUTCHMED Announces that it has Completed Enrollment of a Phase II Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2517132956","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517132956?lang=en_us&edition=fundamental","pubTime":"2025-03-06 18:00","pubTimestamp":1741255200,"startTime":"0","endTime":"0","summary":"The first patient received the first dose in March 2023 and HUTCHMED expects to announce topline results from the study around the end of 2025. If favorable, the results could enable a New Drug Application submission to China’s National Medical Products Administration .Fanregratinib  is a novel, highly selective and potent inhibitor targeting FGFR 1, 2and3. Aberrant FGFR signaling has been found to be a driving force in tumor growth, promotion of angiogenesis and resistance to anti-tumor therapies. Abnormal FGFR gene alterations are believed to be the drivers of tumor cell proliferation in several solid tumor settings.HUTCHMED currently retain all rights to fanregratinib worldwide.This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events, including its expectations regarding the thera","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/hutchmed-announces-completed-enrollment-phase-100000900.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","BK4585","OS","BK4531","PFS","HCM","BK4097","ORR","BK4195","BK4007","BK4211"],"gpt_icon":0},{"id":"2517407989","title":"IO Biotech Reports 2024 Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2517407989","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517407989?lang=en_us&edition=fundamental","pubTime":"2025-03-05 05:17","pubTimestamp":1741123020,"startTime":"0","endTime":"0","summary":"Preparations for submission of a Biologics License Application  for Cylembio  to FDA by year end 2025 remain on track.The trial completed enrollment in December 2023 ahead of plan with 407 patients. The primary endpoint of the pivotal Phase 3 trial is progression free survival ; the rate of PFS events has slowed and the readout of the primary endpoint is now expected in the third quarter of 2025. Dr. Zocca continued, “There is still a significant unmet medical need for new treatment options for patients suffering from advanced melanoma, metastatic head and neck cancer, and metastatic lung cancer. The full IO Biotech team is proud to be leading the next frontier of immune-oncology with the development of therapeutic cancer vaccines for these and other difficult-to-treat cancers. Our investigational therapeutic cancer vaccines are designed with a unique mechanism of action capable of targeting both immune-suppressive cells in the tumor microenvironment  and cancer cells, which have demon","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/io-biotech-reports-2024-business-211700053.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BBT3K403.USD","PFS","LU1057294990.SGD","LU2023250504.SGD","LU0238689110.USD","LU2112291526.USD","IE00BLSP4452.SGD","LU1430594728.SGD","LU0965509010.AUD","01698","BK4534","BK4139","LU0106261372.USD","IE000M9KFDE8.USD","SG9999001176.USD","LU0203345920.USD","IE00BLSP4239.USD","LU0965509283.SGD","LU2468319806.SGD","SG9999002224.SGD","LU0208291251.USD","IE00BYTNYN87.SGD","LU2461242641.AUD","LU0289739699.SGD","IOBT","LU0861579265.USD","LU0266013472.USD","BK4563","LU0006306889.USD","LU0985320562.USD","SG9999001440.SGD","SG9999013999.USD","LU1066051225.USD","BK4559","LU2039709279.SGD","BK4588","TME","SG9999002232.USD","IE00BJJMRZ35.SGD","LU1069347547.HKD","LU1917777945.USD","IE00BJT1NW94.SGD","LU0070302665.USD","SG9999014542.SGD","IE00BN8TJ469.HKD","LU1035773651.USD","BK4195","ORR","MRK","SG9999001176.SGD"],"gpt_icon":0},{"id":"2516363853","title":"Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications","url":"https://stock-news.laohu8.com/highlight/detail?id=2516363853","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516363853?lang=en_us&edition=fundamental","pubTime":"2025-03-03 20:30","pubTimestamp":1741005000,"startTime":"0","endTime":"0","summary":"Naxitamab demonstrated clinically meaningful efficacy with manageable safety in patients with relapsed/refractory high-risk neuroblastoma and residual disease in bone/bone marrowNEW YORK, March  03, 2","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/03/3035507/0/en/Y-mAbs-Announces-Publication-of-Phase-2-Interim-Results-in-Nature-Communications.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4213","ORR","PR","CR","BK4161"],"gpt_icon":0},{"id":"2516760687","title":"Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2516760687","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516760687?lang=en_us&edition=fundamental","pubTime":"2025-03-03 20:01","pubTimestamp":1741003260,"startTime":"0","endTime":"0","summary":"– $7.7 million in Revuforj  net product revenue in initial five weeks of launch –。– Launched Niktimvo  in the U.S. in late January, in partnership with Incyte –。–sNDA filing for revumenib in R/R mNPM1 AML expected in 2Q25 based on positive pivotal data from AUGMENT-101 trial –。–$692.4 million in cash, cash equivalents and investments expected to fund the company to profitability –。NEW YORK, March 03, 2025  -- Syndax Pharmaceuticals , a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the fourth quarter and full year endedDecember 31, 2024, and provided a business update.Reported additional positive results from a post-hoc efficacy analysis of all 77 R/R mNPM1 AML patients who met the efficacy evaluabl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/syndax-reports-fourth-quarter-full-120100660.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2355687059.USD","ASH","LU0985320562.USD","ALL","BK4107","CR","HSTC","LU0456854461.SGD","BK4109","SNDX","LU0266512127.USD","LU2463526074.USD","BK4161","BK4588","BK4585","BK4113","MSS","BK4533","ORR","BK4139","CRC","BK4213","LU1699723380.USD","LU1571399168.USD"],"gpt_icon":0},{"id":"2514324925","title":"Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) previously treated with a BTK inhibitor","url":"https://stock-news.laohu8.com/highlight/detail?id=2514324925","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514324925?lang=en_us&edition=fundamental","pubTime":"2025-02-28 21:14","pubTimestamp":1740748440,"startTime":"0","endTime":"0","summary":"The positive opinion is based on results from the Phase 3 BRUIN CLL-321 trial, recently presented at the 2024 American Society of Hematology Annual Meeting. BRUIN CLL-321 is the first randomized Phase 3 study in CLL ever conducted exclusively in patients previously treated with a BTK inhibitor. The positive opinion is supported by data from the BRUIN CLL-321 clinical trial, the first randomized Phase 3 study in CLL ever conducted exclusively in patients previously treated with a BTK inhibitor. The study's primary endpoint of progression-free survival  was met at the prespecified time of final analysis , based on independent review committee  assessment, demonstrating pirtobrutinib was superior to investigator's choice of idelalisib plus rituximab  or bendamustine plus rituximab , both global standards of care.1 At an updated analysis , pirtobrutinib reduced therisk of disease progressionor death by 46% compared to IdelaR or BR, consistent with the primary analysis.PFS results were cons","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/lillys-jaypirca-pirtobrutinib-recommended-chmp-131400700.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lillys-jaypirca-pirtobrutinib-recommended-chmp-131400700.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1061106388.HKD","LU1974910355.USD","LU2602419157.SGD","ASH","LU0471298777.SGD","LU1267930730.SGD","LU2237443382.USD","LU2063271972.USD","LU1069344957.HKD","LU1023059063.AUD","LU2491050071.SGD","LU0203201768.USD","BK4599","CHMP","LU2237443622.USD","LU2265009873.SGD","LU2237443978.SGD","BK4585","LU2211815571.USD","OS","LU2461242641.AUD","LU0390134368.USD","BR","BK4516","IE0009355771.USD","LU2237443465.HKD","LU2361045086.USD","LLY","SG9999001176.USD","PFS","LU0882574139.USD","LU0203202063.USD","BK4226","PRO","BK4094","IE00BK4W5L77.USD","BNTX","LU0238689110.USD","ORR","LU0640476718.USD","BK4533","BK4109","LU0354030511.USD","FL","BK4588","LU1720051108.HKD","LU1814569148.SGD","IE00BJT1NW94.SGD","SG9999015986.USD","IE0002141913.USD"],"gpt_icon":1},{"id":"2514329672","title":"ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2514329672","media":"Business Wire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514329672?lang=en_us&edition=fundamental","pubTime":"2025-02-28 21:00","pubTimestamp":1740747600,"startTime":"0","endTime":"0","summary":"Recommendation based on DESTINY-Breast06 phase 3 trial results which showed ENHERTU demonstrated superiority versus chemotherapy with a median progression-free survival of more than one year. TOKYO & MUNICH, February 28, 2025----Daiichi Sankyo  and AstraZeneca’s  ENHERTU  has been recommended for approval in the European Union  as a monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor  positive, HER2 low  or HER2 ultralow  breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next line of treatment.ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate  discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.In the DESTINY-Breast06 trial, ENHERTU demonstrated a 38% reduction in the risk of disease progression or death versus chemotherapy in patients with chemotherapy-","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/enhertu-recommended-approval-eu-chmp-130000849.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["DSKYF","CHMP","BK4195","BK4087","BK4156","BK4080","BK4007","BK4203","ORR","BK4211","DSNKY","HR","PBD","PFS","ADC","BK4225","BK4231"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":4,"totalSize":117,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORR\",market:\"US\",delay:false,,,undefined,":{}}}